Specific miRNAs are associated with human cancer cachexia in an organ-specific manner.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2023
Historique:
revised: 07 02 2023
received: 01 09 2022
accepted: 28 02 2023
medline: 5 6 2023
pubmed: 7 4 2023
entrez: 6 4 2023
Statut: ppublish

Résumé

Cancer cachexia (CCx) is a complex and multi-organ wasting syndrome characterized by substantial weight loss and poor prognosis. An improved understanding of the mechanisms involved in the onset and progression of cancer cachexia is essential. How microRNAs contribute to the clinical manifestation and progression of CCx remains elusive. The aim of this study was to identify specific miRNAs related to organ-specific CCx and explore their functional role in humans. miRNA patterns in serum and in cachexia target organs (liver, muscle and adipose tissue) from weight stable (N ≤ 12) and cachectic patients (N ≤ 23) with gastrointestinal cancer were analysed. As a first step, a miRNA array (158 miRNAs) was performed in pooled serum samples. Identified miRNAs were validated in serum and corresponding tissue samples. Using in silico prediction, related genes were identified and evaluated. The findings were confirmed in vitro by siRNA knock-down experiments in human visceral preadipocytes and C2C12 myoblast cells and consecutive gene expression analyses. Validating the results of the array, a 2-fold down-regulation of miR-122-5p (P = 0.0396) and a 4.5-fold down-regulation of miR-194-5p (P < 0.0001) in serum of CCx patients in comparison with healthy controls were detected. Only miR-122-5p correlated with weight loss and CCx status (P = 0.0367). Analysing corresponding tissues six muscle and eight visceral adipose tissue (VAT) cachexia-associated miRNAs were identified. miR-27b-3p, miR-375 and miR-424-5p were the most consistently affected miRNAs in tissues of CCx patients correlating negatively with the severity of body weight loss (P = 0.0386, P = 0.0112 and P = 0.0075, respectively). We identified numerous putative target genes of the miRNAs in association with muscle atrophy and lipolysis pathways. Knock-down experiments in C2C12 myoblast cells revealed an association of miR-27b-3p and the in silico predicted atrophy-related target genes IL-15 and TRIM63. Both were up-regulated in miR-27b-3p knock-down cells (P < 0.05). Concordantly, in muscle tissue of CCx individuals, significant higher expression levels of IL-15 (P = 0.0237) and TRIM63 (P = 0.0442) were detected. miR-424-5p was identified to regulate the expression of lipase genes. Knock-down experiments in human visceral preadipocytes revealed an inverse association of miR-424-5p with its predicted target genes LIPE, PNPLA2, MGLL and LPL (P < 0.01). The identified miRNAs, in particular miR-122-5p, miR-27b-3p, miR-375 and miR-424-5p, represent features of human CCx and may contribute to tissue wasting and skeletal muscle atrophy through the regulation of catabolic signals. Further studies are needed to explore the potential of the identified miRNAs as a screening tool for early detection of cancer cachexia.

Sections du résumé

BACKGROUND
Cancer cachexia (CCx) is a complex and multi-organ wasting syndrome characterized by substantial weight loss and poor prognosis. An improved understanding of the mechanisms involved in the onset and progression of cancer cachexia is essential. How microRNAs contribute to the clinical manifestation and progression of CCx remains elusive. The aim of this study was to identify specific miRNAs related to organ-specific CCx and explore their functional role in humans.
METHODS
miRNA patterns in serum and in cachexia target organs (liver, muscle and adipose tissue) from weight stable (N ≤ 12) and cachectic patients (N ≤ 23) with gastrointestinal cancer were analysed. As a first step, a miRNA array (158 miRNAs) was performed in pooled serum samples. Identified miRNAs were validated in serum and corresponding tissue samples. Using in silico prediction, related genes were identified and evaluated. The findings were confirmed in vitro by siRNA knock-down experiments in human visceral preadipocytes and C2C12 myoblast cells and consecutive gene expression analyses.
RESULTS
Validating the results of the array, a 2-fold down-regulation of miR-122-5p (P = 0.0396) and a 4.5-fold down-regulation of miR-194-5p (P < 0.0001) in serum of CCx patients in comparison with healthy controls were detected. Only miR-122-5p correlated with weight loss and CCx status (P = 0.0367). Analysing corresponding tissues six muscle and eight visceral adipose tissue (VAT) cachexia-associated miRNAs were identified. miR-27b-3p, miR-375 and miR-424-5p were the most consistently affected miRNAs in tissues of CCx patients correlating negatively with the severity of body weight loss (P = 0.0386, P = 0.0112 and P = 0.0075, respectively). We identified numerous putative target genes of the miRNAs in association with muscle atrophy and lipolysis pathways. Knock-down experiments in C2C12 myoblast cells revealed an association of miR-27b-3p and the in silico predicted atrophy-related target genes IL-15 and TRIM63. Both were up-regulated in miR-27b-3p knock-down cells (P < 0.05). Concordantly, in muscle tissue of CCx individuals, significant higher expression levels of IL-15 (P = 0.0237) and TRIM63 (P = 0.0442) were detected. miR-424-5p was identified to regulate the expression of lipase genes. Knock-down experiments in human visceral preadipocytes revealed an inverse association of miR-424-5p with its predicted target genes LIPE, PNPLA2, MGLL and LPL (P < 0.01).
CONCLUSIONS
The identified miRNAs, in particular miR-122-5p, miR-27b-3p, miR-375 and miR-424-5p, represent features of human CCx and may contribute to tissue wasting and skeletal muscle atrophy through the regulation of catabolic signals. Further studies are needed to explore the potential of the identified miRNAs as a screening tool for early detection of cancer cachexia.

Identifiants

pubmed: 37021483
doi: 10.1002/jcsm.13224
pmc: PMC10235869
doi:

Substances chimiques

MicroRNAs 0
Interleukin-15 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1381-1394

Informations de copyright

© 2023 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Methods Mol Med. 2005;107:125-35
pubmed: 15492368
Nucleic Acids Res. 2014;42(17):e133
pubmed: 25063298
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):91-111
pubmed: 29170059
J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):452-463
pubmed: 31828982
Biomolecules. 2021 Feb 13;11(2):
pubmed: 33668431
Crit Rev Oncol Hematol. 2018 Jul;127:91-104
pubmed: 29891116
Front Oncol. 2020 Nov 24;10:607196
pubmed: 33330108
Cancer Med. 2014 Aug;3(4):878-88
pubmed: 24902858
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E191-202
pubmed: 19001550
Am J Physiol Endocrinol Metab. 2014 Feb;306(3):E267-74
pubmed: 24326420
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Front Cell Dev Biol. 2020 Sep 15;8:577010
pubmed: 33043011
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):400-416
pubmed: 29215200
Pharmaceutics. 2022 Jun 29;14(7):
pubmed: 35890276
Oncol Rep. 2014 Apr;31(4):1863-70
pubmed: 24481716
Trends Cancer. 2018 Dec;4(12):849-860
pubmed: 30470306
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Mol Metab. 2020 Apr;34:174-186
pubmed: 32180557
Sci Rep. 2022 Jun 10;12(1):9557
pubmed: 35688898
Mol Syst Biol. 2007;3:138
pubmed: 17893699
Science. 2008 Mar 28;319(5871):1785-6
pubmed: 18369135
J Cachexia Sarcopenia Muscle. 2017 Jun;8(3):405-416
pubmed: 28058815
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13383-7
pubmed: 19666532
Nutr Cancer. 2015;67(7):1056-62
pubmed: 26317149
Obes Surg. 2019 Jul;29(7):2132-2143
pubmed: 30903427
Cell. 2020 Oct 29;183(3):684-701.e14
pubmed: 33058756
Sci Rep. 2019 Jun 20;9(1):8887
pubmed: 31222113
Front Genet. 2020 May 29;11:541
pubmed: 32547603
Biochem Biophys Res Commun. 2008 Aug 15;373(1):20-4
pubmed: 18555009
Cancer Cell Int. 2020 Mar 30;20:98
pubmed: 32256207
Int J Mol Sci. 2019 Apr 22;20(8):
pubmed: 31013615
PLoS One. 2016 Jun 03;11(6):e0157085
pubmed: 27257686
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):536-548
pubmed: 31091026
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 32144431
Nature. 2022 Mar;603(7903):926-933
pubmed: 35296864
Nutr Cancer. 2017 Jan;69(1):84-91
pubmed: 27897439
Int J Clin Exp Pathol. 2017 Sep 01;10(9):9251-9261
pubmed: 31966797
J Cachexia Sarcopenia Muscle. 2023 Jun;14(3):1381-1394
pubmed: 37021483
Drug Discov Today. 2009 Feb;14(3-4):208-13
pubmed: 19041416
Am J Pathol. 2011 Nov;179(5):2580-8
pubmed: 21945323
Biochem J. 2017 Jul 27;474(16):2663-2678
pubmed: 28751550
Mol Cells. 2018 May 31;41(5):390-400
pubmed: 29754469
Cell. 2014 Jan 16;156(1-2):20-44
pubmed: 24439368

Auteurs

Tanja Krauss (T)

Else Kröner-Fresenius Center for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.

Simone Heisz (S)

Else Kröner-Fresenius Center for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.

Julius Honecker (J)

Else Kröner-Fresenius Center for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.

Olga Prokopchuk (O)

Department of Surgery, Klinikum rechts der Isar, University Hospital of the Technical University of Munich, Munich, Germany.

Marc Martignoni (M)

Department of Surgery, Klinikum rechts der Isar, University Hospital of the Technical University of Munich, Munich, Germany.

Klaus-Peter Janssen (KP)

Department of Surgery, Klinikum rechts der Isar, University Hospital of the Technical University of Munich, Munich, Germany.

Melina Claussnitzer (M)

Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Harvard Medical School, Harvard University, Boston, Massachusetts, USA.

Hans Hauner (H)

School of Medicine, Institute of Nutritional Medicine, Technical University of Munich, Munich, Germany.
ZIEL Institute for Food and Health, Technical University of Munich, Freising-Weihenstephan, Germany.
Else Kröner-Fresenius Center for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.

Claudine Seeliger (C)

School of Medicine, Institute of Nutritional Medicine, Technical University of Munich, Munich, Germany.
ZIEL Institute for Food and Health, Technical University of Munich, Freising-Weihenstephan, Germany.
Else Kröner-Fresenius Center for Nutritional Medicine, School of Life Sciences, Technical University of Munich, Freising-Weihenstephan, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH